CING · Cingulate Inc.
$4.68
-0.08 (-1.68%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt about our ability to continue as a going concern for one year after the issuance date of our financial statements.”View the 10-Q filed Aug 13, 2026
Market Cap
$70.46M
Shares
14.54M
Volume · Oct 5
87K
Avg daily vol (3M)
157.46K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.76
Open$4.79
Day$4.71–4.90
52W close$3.33–11.66
Avg vol 30d112K
Short int1.2M · 8.0% float · 13.5d
Short vol39%
Last earningsMay 29, 2025
DataDec 2021–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$28.80M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+200.4%
Year over year · more shares
Price change (1Y)
+17.2%
Trailing year
Short interest
8.0%
Latest settlement · 13.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−12%
below
Price vs 50-day avg
−6%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
17%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−9%
trailing
6-month return
−13%
trailing
YTD return
+10%
this year
Relative strength
−26%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Flat
1 of 40 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.05% of float · ▲ +10.9% MoM · 13.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
40 holders — near 3-yr high, broad support
Squeeze score
72
high risk · 0–100
Fundamentals
EPS growth
+59%
Y/Y
Free cash flow
$-17.4M
Quant / Vol
risk profile
Volatility
88%
annualized · 1-yr
Max drawdown
−69%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−12%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
17%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Flat
1 of 40 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.05% of float · ▲ +10.9% MoM · 13.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
40 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $5 · 17%
Range high $12
vs 200-day avg -12%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CING
this stock
Cingulate Inc.
|
$70.46M | +9.7% | — | — | 8.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CING | -1.5% | -8.8% | -13.5% | -3.8% | +9.7% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -1.2% | -8.4% | -25.6% | -4.8% | -3.2% |